Circulating TNF receptors predict cardiovascular disease in patients with chronic kidney disease

Abstract Cardiovascular disease (CVD) is the main public health problem in patients with chronic kidney disease (CKD); however, there is no established biomarker for predicting CVD morbidity and mortality in CKD. The aim of this study was to evaluate the role of circulating tumor necrosis factor receptors (cTNFRs) in predicting CVD risk in CKD patients. We prospectively recruited 984 patients with CKD from 11 centers between 2006 and 2012. The levels of cTNFR1 and cTNFR2 were determined by performing an enzyme-linked immunosorbent assay. During the mean follow-up period of 4 years, 36 patients experienced a CVD event. The median serum concentrations of cTNFR1 and cTNFR2 were 2703.4 (225.6–13,057.7) and 5661.0 (634.9–30,599.6) pg/mL, respectively, and the cTNFR1 level was closely correlated with the cTNFR2 level (r = 0.86, P < .0001). The urinary protein-to-creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR) were significantly correlated with the cTNFR2 level (r = 0.21 for UPCR, r = −0.67 for eGFR; P < .001 for all). Similar correlations were observed for serum cTNFR1 (r = 0.21 for UPCR, r = −0.75 for eGFR; P < .001 for all). In the Cox proportional hazard analyses, cTNFR1 (hazard ratio [HR] 2.506, 95% confidence interval [CI] 1.186–5.295, P = .016) and cTNFR2 (HR 4.156, 95% CI 1.913–9.030, P < .001) predicted CVD risk even after adjustment for clinical covariates, such as UPCR, eGFR, and high-sensitivity C-reactive protein. cTNFR1 and 2 are associated with CVD and other risk factors in CKD, independently of eGFR and UPCR. Furthermore, cTNFRs could be relevant predictors of CVD in CKD patients.

[1]  M. Meltzer,et al.  Tumor necrosis factor. , 1991, Journal of the American Academy of Dermatology.

[2]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[3]  D. Mele,et al.  Tumor Necrosis Factor- (cid:1) Receptor 1 Is a Major Predictor of Mortality and New-Onset Heart Failure in Patients With Acute Myocardial Infarction The Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) Study , 2005 .

[4]  R. Ardaillou,et al.  Tumor necrosis factor in renal injury. , 1995, Mineral and electrolyte metabolism.

[5]  L. Nilsson,et al.  Soluble TNF Receptors Are Associated with Infarct Size and Ventricular Dysfunction in ST-Elevation Myocardial Infarction , 2013, PloS one.

[6]  A. Schirdewan,et al.  p38 Mitogen-Activated Protein Kinase Inhibition Ameliorates Angiotensin II–Induced Target Organ Damage , 2007, Hypertension.

[7]  M. Kondo,et al.  Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. , 1991, Kidney international.

[8]  P. Libby,et al.  Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. , 1989, Journal of immunology.

[9]  J. Manson,et al.  A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes. , 2005, Diabetes care.

[10]  P. Scheurich,et al.  Tumor necrosis factor signaling , 2003, Cell Death and Differentiation.

[11]  Michael D. Schneider,et al.  TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. , 2007, The Journal of clinical investigation.

[12]  W. Fiers,et al.  Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration. , 1993, The American journal of pathology.

[13]  L. Harrison,et al.  Impaired yield, phenotype, and function of monocyte-derived dendritic cells in humans at risk for insulin-dependent diabetes. , 1998, Journal of immunology.

[14]  R. Sacco,et al.  Tumor Necrosis Factor Receptor Levels Are Associated With Carotid Atherosclerosis , 2002, Stroke.

[15]  W. März,et al.  Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics , 2004, Kidney and Blood Pressure Research.

[16]  C. Peralta,et al.  Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  C. Perez,et al.  A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF , 1988, Cell.

[18]  E. Skovlund,et al.  A simple approach to power and sample size calculations in logistic regression and Cox regression models , 2004, Statistics in medicine.

[19]  Neil R. Powe,et al.  Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. , 2007, Kidney international.

[20]  Y. Kim,et al.  Circulating TNF Receptors Are Significant Prognostic Biomarkers for Idiopathic Membranous Nephropathy , 2014, PloS one.

[21]  R. Sacco,et al.  Soluble tumor necrosis factor receptor 1 level is associated with left ventricular hypertrophy: the northern Manhattan study. , 2009, American Journal of Hypertension.

[22]  H. Brenner,et al.  Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. , 2005, Clinical chemistry.

[23]  G. Hotamisligil.  The role of TNFalpha and TNF receptors in obesity and insulin resistance. , 1999, Journal of internal medicine.

[24]  Margaret S Pepe,et al.  Problems with risk reclassification methods for evaluating prediction models. , 2011, American journal of epidemiology.

[25]  A. Okayama,et al.  Plasma B-type natriuretic peptide level and cardiovascular events in chronic kidney disease in a community-based population. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[26]  A. Schirdewan,et al.  p38 Mitogen-Activated Protein Kinase Inhibition Ameliorates Angiotensin II–Induced Target Organ Damage , 2007, Hypertension.

[27]  Y. Oh,et al.  Circulating tumour necrosis factor receptors 1 and 2 predict contrast‐induced nephropathy and progressive renal dysfunction: A prospective cohort study , 2015, Nephrology.

[28]  W. Ricart,et al.  Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. , 1998, Diabetes.

[29]  P. Vandenabeele,et al.  TNFR1‐ and TNFR2‐mediated signaling pathways in human kidney are cell type‐specific and differentially contribute to renal injury , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  Y. Moriwaki,et al.  Effect of TNF-α inhibition on urinary albumin excretion in experimental diabetic rats , 2007, Acta Diabetologica.

[31]  K. Safranow,et al.  Plasma concentrations of TNF-alpha and its soluble receptors sTNFR1 and sTNFR2 in patients with coronary artery disease. , 2009, Tissue antigens.

[32]  H. Lan,et al.  Therapeutic effects of cytokine blockade in glomerulonephritis. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  D. Fliser,et al.  FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  S. Jacobsen,et al.  Plasma renin activity and risk of cardiovascular and mortality outcomes among individuals with elevated and nonelevated blood pressure , 2016, Kidney research and clinical practice.

[35]  M. Hori,et al.  Involvement of reactive oxygen species-mediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy. , 2002, Journal of molecular and cellular cardiology.

[36]  T. Mayadas,et al.  Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. , 2012, Journal of the American Society of Nephrology : JASN.

[37]  Brenda R. Hemmelgarn,et al.  Notice , 2012, Kidney International Supplements.

[38]  W. G. Walker,et al.  Plasma aldosterone regulation in anephric man. , 1973, Kidney international.

[39]  Y. Moriwaki,et al.  Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. , 2007, Acta diabetologica.

[40]  R. Marfella,et al.  Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in Humans: Role of Oxidative Stress , 2002, Circulation.

[41]  Y. Kim,et al.  Circulating Tumor Necrosis Factor α Receptors Predict the Outcomes of Human IgA Nephropathy: A Prospective Cohort Study , 2015, PloS one.

[42]  Yusuke Suzuki,et al.  Circulating TNF Receptors 1 and 2 Are Associated with the Severity of Renal Interstitial Fibrosis in IgA Nephropathy , 2015, PloS one.

[43]  R. Simsolo,et al.  The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. , 1995, The Journal of clinical investigation.

[44]  L. Lind,et al.  Soluble TNF receptors and kidney dysfunction in the elderly. , 2014, Journal of the American Society of Nephrology : JASN.

[45]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Circulation.

[46]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[47]  L. Tartaglia,et al.  Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. , 1993, The Journal of biological chemistry.

[48]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[49]  M. Woodward,et al.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.

[50]  M. Pfeffer,et al.  Biomarkers of inflammation and progression of chronic kidney disease. , 2005, Kidney international.

[51]  Nam-Ho Kim,et al.  Early Referral to a Nephrologist Improved Patient Survival: Prospective Cohort Study for End-Stage Renal Disease in Korea , 2013, PloS one.

[52]  M. Goicochea,et al.  Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. , 2008, Kidney international. Supplement.

[53]  T. Mayadas,et al.  Immunoregulatory role of TNFalpha in inflammatory kidney diseases. , 2009, Kidney international.

[54]  T. Mayadas,et al.  Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis. , 2005, The Journal of clinical investigation.

[55]  T. Mayadas,et al.  Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. , 2012, Journal of the American Society of Nephrology : JASN.

[56]  G. Hotamisligil.  The role of TNFα and TNF receptors in obesity and insulin resistance , 1999 .

[57]  R. Schreiber,et al.  Ligand-induced Formation of p55 and p75 Tumor Necrosis Factor Receptor Heterocomplexes on Intact Cells* , 1997, The Journal of Biological Chemistry.

[58]  J. Navarro,et al.  Role of inflammation in diabetic complications. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.